Effective June 27, 2023, VSP is making changes to its ophthalmic product formulary to simplify, provide more choice, and reflect brand and technology differentiation.
The changes include:
VSP® regularly reviews its ophthalmic product formulary to ensure it evolves to remain relevant and competitive and reflects industry standards, while allowing VSP members to maximize their benefits at a network practice, like yours. You can find information about the specific changes in the Product Index and the Lens Enhancement Charts located in the Provider Reference Manual on VSPOnline at eyefinity.com. LEGAL NOTICE: Response Required. You have the option to either accept or reject the proposed material changes noted in this letter.
To accept the changes, please provide your electronic signature within thirty (30) days by completing this form.
If you object to the changes, do not complete this form. You must submit all such objections in writing within thirty (30) days after your receipt of this notice. Objections can be directed to: Carey Morris Provider Network Development Manager VSP 3333 Quality Drive, Mailstop 144 Rancho Cordova, CA 95670 800.742.6907 providernetworkdevelopment@vsp.com If you have questions or would like to discuss the changes, please contact your VSP representative or email us at providernetworkdevelopment@vsp.com.
Only Providers in Arkansas, Oregon, West Virginia, and Kansas need to accept the 2023 Formulary changes by signing this form.
Acceptance of the 2023 Ophthalmic Formulary Changes
By typing your name in this box, you are acknowledging you accept the proposed material changes in the letter and charts you received from VSP (and included above).